Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region
Sign Up to like & getrecommendations! Published in 2021 at "Liver Cancer"
DOI: 10.1159/000515817
Abstract: Introduction: Phase 1b GO30140 and phase 3 IMbrave150 studies evaluated first-line atezolizumab + bevacizumab for unresectable hepatocellular carcinoma (HCC). Here, we evaluated pharmacokinetics (PK) and safety by hepatic impairment status and geographic region. Methods: Patients… read more here.
Keywords: bevacizumab; hepatic impairment; impairment status; impairment ... See more keywords